The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Open accessAbstract
Importance: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). Objective: To investigate the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe AD in an identically designed trial. Design, Setting, and Participants: This phase 3, double-blinded, placebo-controlled, parallel-group randomized clinical trial included patients 12 years or older with a clinical diagnosis of moderate-to-severe AD for at least 1 year and inadequate response to topical medications given for at least 4 weeks within 6 months. Patients were enrolled from 115 centers in Australia, Bulgaria, Canada, China, Czechia, Germany, Hungary, Japan, South Korea, Latvia, Poland, United Kingdom, and the United States from June 29, 2018, to August 13, 2019. Data were analyzed from September 13 to October 25, 2019. Interventions: Patients were randomly assigned (2:2:1) to receive once-daily oral abrocitinib in 200- or 100-mg doses or placebo for 12 weeks. Main Outcomes and Measures: The coprimary end points were the proportion of patients achieving Investigator Global Assessment (IGA) response (ie, clear [0] or almost clear [1], with improvement of ≥2 grades) and the proportion of patients achieving at least 75% improvement in Eczema Area and Severity Index score (EASI-75) at week 12. Key secondary end points included the proportion of patients achieving a Peak Pruritus Numerical Rating Scale (PP-NRS) response (ie, improvement of ≥4 points) at week 12. Other secondary end points included the proportion of patients achieving at least 90% improvement in EASI score (EASI-90). Safety was assessed via adverse events and laboratory monitoring. Results: A total of 391 patients (229 male [58.6%]; mean [SD] age, 35.1 [15.1] years) were included in the analysis; of these, 155 received abrocitinib, 200 mg/d; 158, abrocitinib, 100 mg/d; and 78, placebo. Among patients with available data at week 12, greater proportions of patients in the 200- and 100-mg abrocitinib groups vs the placebo group achieved IGA (59 of 155 [38.1%] and 44 of 155 [28.4%] vs 7 of 77 [9.1%]; P < .001) and EASI-75 (94 of 154 [61.0%] and 69 of 155 [44.5%] vs 8 of 77 [10.4%]; P < .001), greater estimated proportions achieved PP-NRS (55.3% [95% CI, 47.2%-63.5%] and 45.2% [95% CI, 37.1%-53.3%] vs 11.5% [95% CI, 4.1%-19.0%]; P < .001), and/or greater proportions achieved EASI-90 (58 of 154 [37.7%] and 37 of 155 [23.9%] vs 3 of 77 [3.9%]) responses. Adverse events were reported for 102 patients (65.8%) in the 200-mg group, 99 (62.7%) in the 100-mg group, and 42 (53.8%) in the placebo group; serious adverse events were reported for 2 patients (1.3%) in the 200-mg group, 5 (3.2%) in the 100-mg group, and 1 (1.3%) in the placebo group. Decreases in platelet count (2 [1.3%]) and laboratory values indicating thrombocytopenia (5 [3.2%]) were reported in the 200-mg group. Conclusions and Relevance: Monotherapy with once-daily oral abrocitinib was effective and well tolerated in adolescents and adults with moderate-to-severe AD. Trial Registration: ClinicalTrials.gov Identifier: NCT03575871.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use
LEWIS-JONES, M. S., & FINLAY, A. Y. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb16953.x · Cited by 1,051
Williams, H., Robertson, C., Stewart, A., Aït-Khaled, N., Anabwani, G., Anderson, R., Asher, I., Beasley, R., Björkstén, B., Burr, M., et al. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70536-1 · Cited by 998
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Charman, C. R., Venn, A. J., & Williams, H. C. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1513 · Cited by 660
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Patient burden and quality of life in atopic dermatitis in US adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., Simpson, E. L., Ong, P. Y., & Chiesa Fuxench, Z. C. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2018.07.006 · Cited by 648
Self-citationSilverberg, J. I., & Hanifin, J. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.031 · Cited by 604
Self-citationTHE INTERNATIONAL CONFERENCE ON HARMONIZATION GOOD CLINICAL PRACTICE GUIDELINE
Dixon, J. R. (1999) · Quality Assurance · doi:10.1080/105294199277860 · Cited by 504
The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society
Carroll, C. L., Balkrishnan, R., Feldman, S. R., Fleischer, A. B., & Manuel, J. C. (2005) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2005.22303.x · Cited by 489
Suárez-Fariñas, M., Tintle, S. J., Shemer, A., Chiricozzi, A., Nograles, K., Cardinale, I., Duan, S., Bowcock, A. M., Krueger, J. G., & Guttman-Yassky, E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1124 · Cited by 464
Conjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442
Self-citationChiesa Fuxench, Z. C., Block, J. K., Boguniewicz, M., Boyle, J., Fonacier, L., Gelfand, J. M., Grayson, M. H., Margolis, D. J., Mitchell, L., Silverberg, J. I., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.08.028 · Cited by 419
Self-citationYosipovitch, G., Reaney, M., Mastey, V., Eckert, L., Abbé, A., Nelson, L., Clark, M., Williams, N., Chen, Z., Ardeleanu, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17744 · Cited by 394
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8488-5 · Cited by 353
Rønnstad, A. T. M., Halling-Overgaard, A.-S., Hamann, C. R., Skov, L., Egeberg, A., & Thyssen, J. P. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.017 · Cited by 352
Self-citationThe Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling
Grozovsky, R., Begonja, A. J., Liu, K., Visner, G., Hartwig, J. H., Falet, H., & Hoffmeister, K. M. (2015) · Nature Medicine · doi:10.1038/nm.3770 · Cited by 336
The molecular regulation of Janus kinase (JAK) activation
Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014) · Biochemical Journal · doi:10.1042/bj20140712 · Cited by 326
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., & Farrar, J. R. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 305
Self-citationGooderham, M. J., Forman, S. B., Bissonnette, R., Beebe, J. S., Zhang, W., Banfield, C., Zhu, L., Papacharalambous, J., Vincent, M. S., & Peeva, E. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.2855 · Cited by 247
Self-citationBurden of skin pain in atopic dermatitis
Vakharia, P. P., Chopra, R., Sacotte, R., Patel, K. R., Singam, V., Patel, N., Immaneni, S., White, T., Kantor, R., Hsu, D. Y., et al. (2017) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.09.076 · Cited by 218
Self-citationPain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L. S., Grayson, M. H., Fuxench, Z. C. C., Simpson, E. L., & Ong, P. Y. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.05.055 · Cited by 126
Self-citationInterleukin-31: A Novel Diagnostic Marker of Allergic Diseases
Rabenhorst, A., & Hartmann, K. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0423-y · Cited by 85
Novel mechanisms of platelet clearance and thrombopoietin regulation
Grozovsky, R., Giannini, S., Falet, H., & Hoffmeister, K. M. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000170 · Cited by 66
Newton, L., DeLozier, A. M., Griffiths, P., Hill, J. N., Hudgens, S. A., Symonds, T. L., Gable, J. C., Paik, J. S., Wyrwich, K. W., Eichenfield, L. F., et al. (2019) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-019-0128-z · Cited by 55
Self-citationDupilumab side effect in a patient with atopic dermatitis: a case report study
Al-Bader, S. S., Alharbi, A. A., Alenezi, R. F., & Alsaif, F. (2019) · Biologics · doi:10.2147/btt.s195512 · Cited by 47
Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis
Hendricks, A. J., Lio, P., & Shi, V. Y. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00436-8 · Cited by 25
Dupilumab side effect in a patient with atopic dermatitis: a case report study
Albader, S. S., Alharbi, A. A., Alenezi, R. F., & Alsaif, F. (2019) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 20
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
Self-citationBlauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3023 · Cited by 516
Self-citationAbrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bieber, T., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C., Pink, A. E., Kataoka, Y., Chu, C.-Y., DiBonaventura, M., Rojo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2019380 · Cited by 476
Self-citation
Metadata
- Authors
- Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C., & Rojo, R.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-08-01
- Volume
- 156
- Issue
- 8
- Pages
- 863
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W3032018657
- Cited by
- 404
- References
- 36
- FWCI
- 37.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.